Table 1_Association of long-term 5α-reductase inhibitor use with survival in men with rena

A retrospective cohort study of 31,927 men with newly diagnosed renal cell carcinoma (RCC) from the Korean National Health Insurance Service database (2007–2020). The research, authored by Sieun Lee, investigates the association between long-term use of 5α-reductase inhibitors and all-cause mortality, finding a significant survival benefit in certain patient subgroups.

Use Cases

• Survival analysis based on long-term medication use and patient comorbidity scores.
• Propensity score matching to evaluate treatment effects in observational data.
• Subgroup analysis to identify patient populations that may benefit most from a specific drug class.
• Investigating sex-based differences in cancer progression and mortality.

Strengths

• Based on a nationwide population cohort of 31,927 eligible men, providing a substantial sample size.
• Employs propensity score matching (1:3 ratio) to balance baseline characteristics like age and comorbidity burden.
• Reports specific hazard ratios and confidence intervals for primary and subgroup analyses, such as HR: 0.88 (95% CI: 0.79–0.94).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the final matched analytic dataset (1,803 users + 5,409 non-users) is provided, but the full underlying data structure is unknown.
• Data may reflect geographic and temporal bias inherent to the Korean National Health Insurance Service database from 2007–2020.

Provenance

Source

Korean National Health Insurance Service database.

Collection Method

Population-based retrospective cohort study using administrative health data.

Time Range

2007–2020

Freshness

Last updated 2026-05-22 05:35:55; freshness should be verified.

Geography

South Korea